Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Processed

United States — Food and Drug Administration & Marty Makary

25 shared events · Importance 4 · Last updated Sep 08, 2026

Importance
4
Shared Events
25
Actions
1
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
77
Domestic
United States — Food and Drug Administration: The FDA is the agency being led. It faces staff losses, morale issues, and policy controversies; Overton's nomination could exacerbate these challenges.
Marty Makary: Makary resigned as FDA commissioner in May after clashes with the White House. His departure created the vacancy Overton is nominated to fill.
Aug 19, 2026 · 101 articles
71
Regulatory
United States — Food and Drug Administration: The FDA gains permanent leadership in key centers, restoring stability after months of turnover. This affects its regulatory operations and relationships with regulated industries.
Marty Makary: Makary's resignation as FDA Commissioner in May contributed to the leadership upheaval; his policies on vaccines and tobacco drew criticism.
Sep 08, 2026 · 6 articles
65
Regulatory
United States — Food and Drug Administration: The FDA, under Commissioner Marty Makary, enacted regulations to phase out petroleum-based food dyes, driving the industry's shift. Its actions create regulatory pressure that affects all food companies.
Marty Makary: As FDA Commissioner, Makary enacted regulations to phase out synthetic dyes and linked them to health risks, catalyzing the industry's move toward natural colors.
Aug 26, 2026 · 6 articles
63
Regulatory
United States — Food and Drug Administration: The FDA granted approval for mFLUSIVA, marking a regulatory milestone and demonstrating its role in vaccine oversight despite internal controversies.
Marty Makary: Makary, former FDA Commissioner, faced criticism for vaccine scrutiny and resigned amid controversies.
Aug 05, 2026 · 105 articles
63
Regulatory
United States — Food and Drug Administration: The FDA is the subject of the restructuring, which could reshape its leadership and regulatory approach, affecting drug approvals and AI oversight.
Marty Makary: Makary's resignation in May created the leadership vacuum that led to the current restructuring.
Aug 25, 2026 · 6 articles
52
Regulatory
United States — Food and Drug Administration: The agency at the center of the nomination, facing leadership change and policy shifts on vaccines, mifepristone, and vaping; it has lost about 20 percent of staff since Trump took office.
Marty Makary: Previous FDA commissioner who resigned in May after a tenure marked by scientific disputes and low morale; Overton studied under him at Johns Hopkins.
Sep 24, 2026 · 12 articles
42
Regulatory
United States — Food and Drug Administration: Regulatory body that approved Lipfendra, enabling market entry.
Marty Makary: Former FDA chief who created the accelerated review pathway used for Lipfendra; resigned in May 2026.
Jul 16, 2026 · 93 articles
32
Regulatory
United States — Food and Drug Administration: The FDA granted expedited approval to daraxonrasib, marking a regulatory milestone and demonstrating its commitment to accelerating cancer treatments. The approval was issued 6.5 months ahead of schedule, reflecting the agency's priority review process.
Marty Makary: Former FDA Commissioner Marty Makary initiated the Commissioner's National Priority Voucher Program, under which the drug was reviewed, contributing to the expedited approval.
Aug 26, 2026 · 92 articles
14
Domestic
United States — Food and Drug Administration: The FDA is mentioned as another agency with a leadership vacancy, but it is not directly involved in this event.
Marty Makary: Makary's resignation as FDA commissioner contributed to the leadership vacuum in health agencies.
Jul 15, 2026 · 148 articles
10
Business
United States — Food and Drug Administration: The FDA granted Breakthrough Therapy Designation to BPL-003 and announced regulatory actions to support psychedelic drug development, facilitating the path to market.
Marty Makary: Marty Makary, former FDA commissioner, commented on the FDA's regulatory actions supporting psychedelic therapeutics.
Jul 16, 2026 · 25 articles
0
Regulatory
Marty Makary: As Food and Drug Commissioner, Marty Makary signaled the administration's stance on saturated fats and commented on protein guidance.
Jan 07, 2026 · 7 articles
0
Regulatory
Marty Makary: As the Commissioner of the United States — Food and Drug Administration, Marty Makary is a key figure in implementing the new policy to reduce the number of required studies for drug approval, aiming to speed up drug development.
Feb 18, 2026 · 6 articles
0
Regulatory
Feb 18, 2026 · 9 articles
0
Regulatory
Mar 10, 2026 · 8 articles
0
International
Marty Makary: Marty Makary is resigning as the head of the United States — Food and Drug Administration due to difficulties and complaints from health industry executives, anti-abortion activists, and other Trump allies.
May 12, 2026 · 18 articles
0
International
Marty Makary: Marty Makary resigned as the head of the United States — Food and Drug Administration after a rocky tenure and complaints from various industry groups.
Apr 16, 2026 · 760 articles
0
Regulatory
Marty Makary: Marty Makary resigned as United States — Food and Drug Administration Commissioner, having engineered Tracy Beth Høeg's rapid rise and facing criticism from political allies.
May 15, 2026 · 17 articles
0
International
Marty Makary: Marty Makary resigned as the United States — Food and Drug Administration Commissioner, contributing to the agency's leadership upheavals.
May 12, 2026 · 17 articles
0
Domestic
Marty Makary: Marty Makary resigned as head of the United States — Food and Drug Administration, widening the leadership gap within the United States — United States Department of Health and Human Services and leaving behind unfinished initiatives.
May 13, 2026 · 6 articles
0
Domestic
Marty Makary: Marty Makary>>> resigned as Commissioner of the United States — Food and Drug Administration>>> after a tumultuous tenure marked by clashes with the Donald Trump>>> administration, industry, and public health groups. His departure creates uncertainty for several of his initiatives.
May 08, 2026 · 114 articles
0
International
Marty Makary: Marty Makary is resigning as the head of the United States — Food and Drug Administration after a rocky tenure, drawing complaints from various industry executives and activists.
Apr 30, 2026 · 116 articles
0
Regulatory
May 06, 2026 · 7 articles
0
Regulatory
Apr 18, 2026 · 29 articles
0
Tech
Apr 23, 2026 · 7 articles
0
Regulatory
Marty Makary: Former United States — Food and Drug Administration Commissioner Marty Makary had indicated that reviewing the benefits of MDMA and other psychedelics was a top priority, though his resignation may impact the pace of review.
May 26, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States — Food and Drug Administration and Marty Makary interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.